From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Complete Protection Against Yersinia pestis by Immunization with Inhalable rF1-V10 Fusion Protein

by Global Biodefense Staff
February 2, 2022
Dynavax and DoD Announce Collaboration to Develop an Adjuvanted Plague Vaccine

Background image: magnified 1125X gram-negative, rod-shaped, Yersinia pestis bacteria. Credit: D.S. Martin / CDC

The capsular antigen F1, the low-calcium-response V antigen (LcrV), and the recombinant fusion protein (rF1-LcrV) of Yersinia pestis, are leading subunit vaccine candidates under intense investigation; however, the inability of recombinant antigens to provide complete protection against pneumonic plague in animal models remains a significant concern.

Inhalation delivery of vaccines has received increasing attention due to its ability to recruit local immune responses of the bronchopulmonary mucosa in addition to the broader systemic immune response.

For more than 70 years, the Y. pestis EV NIIEG strain has been used as a human plague vaccine in the former Soviet Union and confers protection against bubonic and pneumonic plague after administration via inhalation. However, the protection appears to be short-lived and the vaccine is highly reactogenic, limiting licensing of this vaccine for use in many parts of the world. The preparation of live Y. pestis dry powder is rarely reported in the literature, possibly because of bacterial viability being lost during preparation. Subunit vaccine candidates may thus prove a better option for inhalable powder.

In this study, researchers explore the immunogenicity and protective efficacy of three subunit vaccines in different formulations (liquid, powder and reconstituted powder) via intratracheal and subcutaneous administration routes in a mouse model of Y. pestis intratracheal infection.

The results demonstrate preclinical feasibility of using a powder formulation of rF1-V10 and the potential use of an alternative pulmonary delivery method as a promising vaccination strategy.

Complete Protection Against Yersinia pestis in BALB/c Mouse Model Elicited by Immunization With Inhalable Formulations of rF1-V10 Fusion Protein via Aerosolized Intratracheal Inoculation. Frontiers in Immunology, 26 January 2022.

From Our Partners
Tags: Animal ModelsEditor PickSelect AgentsY. pestis

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC